Tumefactive demyelination presenting during bevacizumab treatment

Claire M Rice; David Rossiter; Janev Fehmi; James C Stevens; Shelley A Renowden; Nicki Cohen; Clare Bailey; Neil J Scolding

doi:10.1136/bcr-2015-212173

Tumefactive demyelination presenting during bevacizumab treatment

Claire M Rice
, David Rossiter
, Janev Fehmi
, James C Stevens
, Shelley A Renowden
, Nicki Cohen
, Clare Bailey
, Neil J Scolding

Research output: Contribution to journal › Article (Academic Journal) › peer-review

5 Citations (Scopus)

Abstract

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

Original language	English
Journal	BMJ Case Reports
Volume	2015
DOIs	https://doi.org/10.1136/bcr-2015-212173
Publication status	Published - 2015

Access to Document

10.1136/bcr-2015-212173

Handle.net

Persistent link

Cite this

@article{786074a6ef8a4996a38d26a9a9e49557,

title = "Tumefactive demyelination presenting during bevacizumab treatment",

abstract = "We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.",

author = "Rice, \{Claire M\} and David Rossiter and Janev Fehmi and Stevens, \{James C\} and Renowden, \{Shelley A\} and Nicki Cohen and Clare Bailey and Scolding, \{Neil J\}",

year = "2015",

doi = "10.1136/bcr-2015-212173",

language = "English",

volume = "2015",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Tumefactive demyelination presenting during bevacizumab treatment

AU - Rice, Claire M

AU - Rossiter, David

AU - Fehmi, Janev

AU - Stevens, James C

AU - Renowden, Shelley A

AU - Cohen, Nicki

AU - Bailey, Clare

AU - Scolding, Neil J

PY - 2015

Y1 - 2015

N2 - We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

AB - We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

U2 - 10.1136/bcr-2015-212173

DO - 10.1136/bcr-2015-212173

M3 - Article (Academic Journal)

C2 - 26677151

SN - 1757-790X

VL - 2015

JO - BMJ Case Reports

JF - BMJ Case Reports

ER -

Tumefactive demyelination presenting during bevacizumab treatment

Abstract

Access to Document

Handle.net

Fingerprint

Cite this